Skip to Main content Skip to Navigation
New interface
Journal articles

Management of sleep apnoea syndrome (SAS) in patients with vasovagal syncope (VVS): a protocol for the VVS-SAS cohort study

Abstract : Introduction Recurrent vasovagal syncope (VVS) is associated with decreased quality-of-life and frequent use of emergency services. The evidence base for causality, diagnostic procedures and potential VVS treatments is poor. Scattered observations in the literature suggest a link between respiratory disturbances during sleep and VVS. Empirical observations lead us to further hypothesise that the appropriate management of sleep apnoea syndrome (SAS) may help resolve comorbid recurrent VVS in certain patients. We therefore designed this pilot study to provide a framework for the observation of changes in outcomes accompanying the deployment of SAS treatments in patients with VVS. Methods and analysis This is a multicentre, registrybased study whose primary objective is to evaluate the effect of SAS management on the number of syncope/ presyncope episodes in a population suffering from both VVS and SAS. To this effect, syncope rates prior to the treatment of SAS will be compared with those occurring after the initiation of the latter. In addition, yearly assessments will collect data for echocardiography, polysomnography, Holter monitoring, table tilt tests, multiple sleep latency tests, SAS management parameters and questionnaires describing fatigue, depression and quality-of-life. Sixty patients will be included with a minimum follow-up period of 12 months. The primary analysis will use comparisons of centrality for paired data to describe the changes in syncope rates before versus after the initiation of SAS management. Longitudinal data will be analysed using mixed models with patients set as a random effect. Subgroup analyses will be performed for SAS-treatment adherence and efficacy. Ethics and dissemination The VVS-SAS registry was approved by an ethics committee (Comité pour la Protection des Personnes Ile-de-France VI, Reference number CPP/2-18) in accordance with French law. The princeps publication will present before-after SAS management results and longitudinal analyses. Trial registration number NCT04294524. Pre-results. *Symptoms are triggered by orthostatism and can include presyncopes without loss of consciousness, asthenia, dizziness, visual disturbances, tinnitus, palpitations, headache, limitations of physical activity.
Complete list of metadata
Contributor : régis Guieu Connect in order to contact the contributor
Submitted on : Monday, February 22, 2021 - 4:58:09 PM
Last modification on : Friday, September 9, 2022 - 10:20:08 AM
Long-term archiving on: : Sunday, May 23, 2021 - 7:07:09 PM


Publisher files allowed on an open archive


Distributed under a Creative Commons Attribution 4.0 International License



Vincent Puel, Isabelle Godard, Georgios Papaioannou, Philippe Gosse, Jean Louis Pepin, et al.. Management of sleep apnoea syndrome (SAS) in patients with vasovagal syncope (VVS): a protocol for the VVS-SAS cohort study. BMJ Open, 2020, 10 (9), pp.e038791. ⟨10.1136/bmjopen-2020-038791⟩. ⟨hal-03149023⟩



Record views


Files downloads